1. Hypofractionated radiotherapy to become the new standard of care – 5 year results from the CHHiP trial
The long-awaited CHHiP (Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer) trial results were published last month in Lancet Oncology. The phase 3 non-inferiority trial, led by the ICR’s Prof David Dearnaley and involving 3,163 participants, showed that hypofractionated radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy in 37 fractions. The study recommended this as a new standard of care for external-beam radiotherapy of localised prostate cancer (since men can now make 17 fewer hospital trips without compromising on effectiveness) and we are working with Prof Dearnaley’s team to ensure widespread roll-out.
Read about the trial results in more detail on our website here.